Introduction
============

In tinnitus, the patient experiences abnormal auditory sensation without any evidence of an external acoustic stimulus. Tinnitus is classified into two types; objective and subjective. In the former, the noise heard has a physical explanation and is also perceived by the examiner, while in the latter type, the noise input *is*perceptible by the patient alone ([@B1],[@B2]).

Subjective tinnitus is a relatively common disorder with a prevalence of approximately 32% in the United States of America ([@B3]). Several approaches for the treatment of tinnitus have been tried, including use of a tinnitus masker, biofeedback, electrical stimulation, hearing aids, surgical therapy, antidepressants, anxiolytics agents, and lidocaine, for example ([@B4]-[@B8]). However, these investigations are inconclusive and have shown limited success, with low patient satisfaction.

Because cerebral activity is altered in tinnitus, scientists have suggested alternative therapeutic approaches, such as anticonvulsant agents ([@B9],[@B10]). The anticonvulsant agent, gabapentin, increases the synthesis of gamma-aminobutyric acid (GABA) in the brain and improves inhibitory neurotransmitter GABA activity. Moreover similar to lidocaine, gabapentin can inhibit voltage-activated Na^+^ channels ([@B11]). A study in rat models revealed that administration of salicylates decreases GABA and the affinity of the GABA receptors in the brain and induces the sensation of tinnitus and hearing loss ([@B12]). In keeping with this investigation, another study in rats reported that the reduction of GABA levels in the inferior colliculus induced hearing loss in these animals ([@B13]). Similarly, a further study on rat models documented that gabapentin significantly decreases tinnitus compared with placebo ([@B14]). Despite the positive results of gabapentin in the treatment of tinnitus, reports of the investigations are conflicting and most recommend further randomized clinical trials in order to evaluate the impact of gabapentin on tinnitus. Therefore, we conducted this double-blind, randomized clinical trial in order to compare the effect of gabapentin with placebo on the sensation of subjective tinnitus in patients with acoustic trauma.

Materials and Methods
=====================

*Patients:*This double-blind, randomized clinical trial recruited 103 patients who were referred to the ear, nose, and throat (ENT) clinic of Taleghani Hospital in 2014 with subjective tinnitus after sound trauma. Patients were excluded if they met any of the listed exclusion criteria.

*Exclusion Criteria:*

Exclusion criteria were as follows: acute or chronic otitis; history of diseases such as thyroid, rheumatoid or renal diseases; pregnancy; intake of drugs such as aspirin, aminoglycosides, or diuretics; use of chemotherapy agents such as cisplatin; age greater than 50 years and less than 18 years. In addition, patients presenting with tinnitus not due to sound trauma, such as vascular or psychiatric disorders or presbycusis, were excluded. A magnetic resonance imaging (MRI) scan and auditory brainstem response test were performed in all patients with neurologic symptoms or any central nervous system complication. The study was explained to all patients before enrolment, and signed informed written consent was taken. In addition, the study was approved by the ethics committee of Shahid Beheshti University of Medical Sciences.

*Study Design:*

Patients were interviewed and demographic information such as age, sex, and employment status were recorded before auditory tests were performed in all patients. Patients were then randomized into two groups using sequential numbers such that the first number was given to the first patient who was then allocated gabapentin 300 mg/daily (gabapentin group, or case group, n=55). The next patient was given the next number sequentially, and allocated placebo therapy in the form of matching capsules (control group, n=48). The two groups were administered capsules twice a day. Both participants and study staff (site investigators and trial coordinating center staff) were blinded to treatment allocation.

Pure tone audiometry was used for auditory measurements, and the average thresholds at 500, 1000, and 2000 Hz was determined for assessment.

The severity of tinnitus was measured based on a visual analog scale (VAS) before treatment initiation and after 6 weeks of therapy. VAS is a psychometric evaluation of tinnitus severity consisting of 11 questions, in which the patient is asked to respond to each question on a scale from 0 to 10. Responses were recorded on a straight line on a graded scale, and the numerical charts were determined by the patient ([@B15],[@B16]).

A reduction of more than 30% in the VAS was considered the minimum response to treatment. Patients were asked to refer to the ENT clinic in case of fever, drowsiness, or dizziness.

*Statistical Analyses*

Data were analyzed using SPSS Version 22. Categorical data are presented as numbers (%) and continuous data as mean ± standard deviation (SD). We used the Chi-square test to compare categorical variables and the Student's t-test and paired t-test to compare continuous variables. p\<0.05 was considered statistically significant.

Results
=======

This study evaluated 103 patients (55 male and 48 female) in two groups, with a mean age of 37.6 years and a mean duration of disease of 4.2 years. Most patients in each group were employed. Differences between the two groups regarding sex, age, duration of disease, and job were not significant. In addition, there were no significant differences in audiometry tests between the two groups ([Table.1](#T1){ref-type="table"}).

###### 

Patient characteristics and Audiometry test in the two study groups.

  **Variable**      **Gabapentin**   **Control**   **P** ***-*** **value**   
  ----------------- ---------------- ------------- ------------------------- ------
  Age               Year             38.60±8.15    37.16±8.87                0.36
  Sex               Male             44 (80%)      29 (60.4%)                0.02
  Female            11 (20%)         19 (39.6%)                              
  Job               Worker           28 (42%)      19 (40%)                  0.18
  Employee          8 (14.4%)        16 (33%)                                
  Army              11 (19.6%)       6 (12.5%)                               
  Others            8 (14.4%)        7 (14.5%)                               
  Duration (year)   Year             4.76±6.85     3.35±2.24                 0.19
  Audiometry test   Right ear        10 (18.2%)    10 (18.2%)                0.19
                    Left ear         13 (23.6%)    12 (25.0%)                
                    Bilateral        32 (58.2%)    26 (54.2%)                

There was no significant difference in mean VAS between the two groups before treatment; however, after treatment the VAS score was significantly lower in the gabapentin group than the control group ([Table.2](#T2){ref-type="table"}, [Fig.1](#F1){ref-type="fig"}). In addition, the difference between pre- and post-treatment in each group was significant. Furthermore, the number of patients achieving at least a 30%

decrease in VAS (response to treatment) was significantly greater in the gabapentin group compared with the control group ([Table.2](#T2){ref-type="table"}).

The correlation of response to gabapentin with age (P=0.83), disease duration (P=0.55), and sex (P=0.08) was not significant; however, response to gabapentin was significantly correlated with the employment status of the patient (P=0.01).

###### 

Between-group differences in each group before and after treatment based on the visual analog scale

  **Visual analogue scale**                      **Before treatment**   **After treatment**   **95% CI**         **P** **-value (paired t-test)**
  ---------------------------------------------- ---------------------- --------------------- ------------------ ----------------------------------
  Gabapentin                                     7.56±1.01              3.07±1.11             4.10--4.87         \<0.001
  Control                                        7.31±1.01              4.60±1.25             2.28--3.12         \<0.001
  P-value (t-test)                               0.21                   \<0.001                                  
  ≥30% decrease in VAS (response to treatment)   Gabapentin             Control               P-value (t-test)   
  49(89%)                                        28(58%)                \<0.001                                  

![Severity of tinnitus based on a visual analog scale before and after 6 weeks of treatment in the two study groups](ijo-29-095-g001){#F1}

Discussion
==========

Gabapentin has been used widely in several disorders, including seizure, anxiety, and pain. Researchers have demonstrated a high-affinity binding site in the synapses and have shown that gabapentin decreases the level of neurotransmitters by binding with calcium channel proteins and imitating the action of the inhibitory neurotransmitter GABA ([@B17]).

In the current randomized clinical trial, we compared the efficacy of gabapentin with placebo in patients with tinnitus referring to the ENT clinic because of acoustic trauma. The VAS and the Tinnitus Handicap Inventory (THI) are frequently used for the assessment of tinnitus. Although the THI is the most widely accepted method of tinnitus evaluation, the VAS tool is traditionally used, and there are a number of studies demonstrating a good correlation between VAS and THI scores. Thus, the VAS continues to be used as an appropriate method of measuring the intensity of *tinnitus* ([@B18],[@B19]).

We found that gabapentin significantly decreased the VAS score in patients with tinnitus due to acoustic trauma. Moreover, gabapentin significantly increased the frequency of patients responding to treatment (≥30% decrease in VAS). Similar findings were reported in 2001 by Zapp et al. who indicated that gabapentin 500 mg daily increased the number of tinnitus-free days to 23 days/month ([@B20]). Similarly, in 2002 Shulman et al. revealed that the combination of gabapentin and clonazepam decreased the severity of tinnitus in 94.3% of patients with disabling tinnitus ([@B21]); a finding that was consistent with a 2001 investigation on psychophysical rat models ([@B14]). In addition, a study by Bauer and Brozoski indicated that gabapentin significantly decreased the loudness of tinnitus in adult patients who had a history of acoustic trauma ([@B22]). However, the results of treatment with gabapentin are not consistent, and some authors reported no significant effect of using gabapentin in tinnitus. For example, a 2011 controlled trial by Dehkordi et al. indicated that gabapentin had no positive effect on the treatment of tinnitus compared with placebo, although they reported that patients with hypertension, diabetes, and dyslipidemia all improved to a greater degree following treatment with gabapentin ([@B23]). Moreover, in double-blind clinical trials, Piccirillo et al. ([@B24]), Witsell et al. ([@B25]), and Bakhshaee et al. ([@B26]) concluded that the efficacy of gabapentin was not superior to placebo. Additionally, consistent with these findings, another study by Bahmad et al. investigating combination therapy with GABAergics and benzodiazepines in patients with severe tinnitus did not reveal any significant improvement among patients ([@B27]). The differences among these studies may be related to several factors such as differences in patient selection and methodology; moreover the definition of improvement may differ in these trials.

In the current study, the two groups were properly matched and differences in sex, age, and duration of disease were not significant between two groups, and thus had no effect on tinnitus response to gabapentin. However, the patients\' employment status correlated with the results of treatment. Consistent with our investigation, Dehkordi et al. showed that a positive history of acoustic trauma, tinnitus sound type, accompanying symptoms, and duration of tinnitus had no impact on the outcome of treatment ([@B23]). Moreover, a review by Aazh et al. ([@B28]) was also in line with these findings, and did not reveal any correlation between duration of tinnitus and disease improvement. However, Aazh et al. indicated that the tinnitus duration may impact on treatment outcomes and patients, with a longer tinnitus duration leading to less improvement after treatment with gabapentin ([@B28]). A further study, by Otsuka et al., revealed that tinnitus patients aged more than 60 years showed a better response to intravenous lidocaine ([@B29]).

In summary, in the present trial we treated a case group of tinnitus patients with gabapentin 300 mg bid and found this to be an effective treatment. However, previous practices have used gabapentin at higher doses (600--1800 mg bid); therefore we recommend that gabapentin is initiated at minimum doses and increased if required. Although this study demonstrates strong evidence in favor of tinnitus treatment with gabapentin, some study limitations should be noted, such as the relatively small sample size and short duration of follow-up (6 weeks). These shortcomings may limit our ability to generalize the results of the present survey. Further analyses with larger series of patients and a longer duration of follow-up are required to determine whether gabapentin is an effective treatment for acoustic tinnitus.

Conclusion
==========

We conclude that 6 weeks' treatment with gabapentin 300 mg bid is effective in patients with acoustic tinnitus. In addition, the placebo effect in decreasing tinnitus in these patients is remarkable.

We are grateful to all participating hospitals, ENT clinics, and general practitioners for their assistance in implementing this study and thank all of the patients who participated for their cooperation.
